Table 3.
Baseline Characteristics in Validation Cohort (N=6,332)
| SDNN* | rMSSD* | |||||
|---|---|---|---|---|---|---|
| Characteristic | All participants (n=6,332) |
Borderline Abnormal (n=494) |
Abnormal (n=198) |
Borderline Abnormal (n=478) |
Abnormal (n=170) |
|
| Age, mean±SD, years | 62±10 | 67±9.4 | 68±9.4 | 66±9.7 | 66±10 | |
| Male (%) | 2,944 (46) | 243 (49) | 82 (41) | 227 (47) | 60 (35) | |
| Race/Ethnicity | ||||||
| White (%) | 2,410 (38) | 200 (40) | 89 (45) | 197 (41) | 60 (35) | |
| Chinese-American (%) | 767 (12) | 68 (14) | 19 (10) | 61 (13) | 17 (10) | |
| Black (%) | 1,727 (27) | 137 (27) | 44 (22) | 136 (28) | 41 (24) | |
| Hispanic (%) | 1,428 (23) | 92 (19) | 46 (23) | 84 (18) | 52 (31) | |
| Education, high school or less (%) | 2,315 (37) | 211 (43) | 91 (46) | 198 (41) | 80 (47) | |
| Income, <$20,000 (%) | 1,688 (27) | 171 (35) | 78 (39) | 165 (35) | 73 (43) | |
| Ever smoker (%) | 3,136 (50) | 251 (51) | 95 (48) | 240 (50) | 69 (41) | |
| Diabetes (%) | 889 (14) | 143 (29) | 65 (33) | 134 (28) | 54 (32) | |
| Body mass index, mean±SD, kg/m2 | 28±5.5 | 29±5.9 | 29±6.3 | 29±5.9 | 29±6.3 | |
| Systolic blood pressure, mean±SD, mm Hg | 126±21 | 133±21 | 135±23 | 132±21 | 134±23 | |
| Total cholesterol, mean±SD, mg/dL | 194±36 | 194±37 | 193±34 | 195±37 | 194±35 | |
| HDL cholesterol, mean±SD, mg/dL | 51±15 | 51±15 | 51±15 | 51±15 | 52±15 | |
| Antihypertensive medications (%) | 2,312 (37) | 245 (50) | 111 (56) | 234 (49) | 90 (53) | |
| Aspirin (%) | 1,470 (23) | 152 (31) | 67 (34) | 149 (31) | 54 (32) | |
| Statin (%) | 927 (15) | 99 (20) | 46 (23) | 89 (19) | 31 (18) | |
| Left ventricular hypertrophy (%) | 237 (3.7) | 27 (5.5) | 11 (5.6) | 22 (4.6) | 13 (7.7) | |
*
Borderline abnormal and abnormal values defined as <5th and <2nd percentiles for the sex- and race-specific references ranges, respectively.
HDL=high-density lipoprotein; LDL=low-density lipoprotein; SD=standard deviation.